Immuneering Corp. (IMRX)
5.16
+0.21
(+4.24%)
USD |
NASDAQ |
Mar 04, 15:08
Immuneering Research and Development Expense (Annual) : 47.72M for Dec. 31, 2024
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Vanda Pharmaceuticals, Inc. | 109.27M |
| Verastem, Inc. | 81.33M |
| Phathom Pharmaceuticals, Inc. | 32.78M |
| Tango Therapeutics, Inc. | 143.92M |
| Moderna, Inc. | 2.917B |